April 2022 – A major study elucidating the mechanism of action of the IBD-asset has been completed: Alma’s treatment facilitates mucosal healing without immune suppression
March 2022 – WO 2022/070052 A1, a new PCT covering the effect of our IBD-asset on gut dysbiosis and impaired barrier function, was published online.
February 2022 – Alma attended ECCO 2022, the 17th congress of European Crohn’s and Colitis Organisation
March 2021 – Alma Bio Therapeutics presented in the biotech session of the special webinar “Bouncing back from the crisis. How to re-establish partnerships between
January 2021 – Alma Bio Therapeutics attended the 4th Antigen Specific Immune Tolerance digital event.
September 2020 – Prof. Francisco Javier Quintana of Brigham and Women’s Hospital Harvard Medical School, a world-renowned expert in immune regulation and tolerance, joins Alma’s
July 2020 – Alma Bio Therapeutics was among the recipients of PGE, the French government state guaranteed loan.
March 2020 – Alma Bio Therapeutics participated at Digital BioEurope Spring
March 2020 – Alma Bio Theraeutics presented at the RESI Digital partnering event
December 2019 – Alma Bio Therapeutics will be attending the French-Israeli joint event in the healthcare sector, Paris December 10, 2019, sponsored by the BPI, the
December 2019 – Alma has been invited to present at the EIT Health Summit 2019, December 2-3 Paris. Come and meet us there.
October 2019 – Alma receives the EMA’s CHMP (Committee for Medicinal Products for Human Use) scientific advice. The Agency’s advice concerned quality development, pre-clinical development
August 2019 – Alma is featured in Cello Health BioConsulting’s “Next-generation-therapies-for-autoimmune-and-inflammatory-diseases”. Alma is listed among the “next generation approaches in development with novel targets and